These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22450392)

  • 61. Targeting vascular disease in systemic sclerosis.
    Kowal-Bielecka O
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Systemic sclerosis-associated fibrosis: an accelerated aging phenotype?
    Luckhardt TR; Thannickal VJ
    Curr Opin Rheumatol; 2015 Nov; 27(6):571-6. PubMed ID: 26398012
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
    Fallet B; Walker UA
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1203-1218. PubMed ID: 33008265
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.
    Roofeh D; Lescoat A; Khanna D
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):455-466. PubMed ID: 33054463
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Novel investigational agents for the treatment of scleroderma.
    McMahan ZH; Wigley FM
    Expert Opin Investig Drugs; 2014 Feb; 23(2):183-98. PubMed ID: 24261610
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
    Bhattacharyya S; Wei J; Varga J
    Nat Rev Rheumatol; 2011 Oct; 8(1):42-54. PubMed ID: 22025123
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular targets for therapy in systemic sclerosis.
    Iwamoto N; Distler O
    Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S19. PubMed ID: 23259845
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
    McGaugh S; Kallis P; De Benedetto A; Thomas RM
    Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeted delivery in scleroderma fibrosis.
    Varrica C; Dias HS; Reis C; Carvalheiro M; Simões S
    Autoimmun Rev; 2021 Feb; 20(2):102730. PubMed ID: 33338593
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.
    Young A; Khanna D
    Curr Opin Rheumatol; 2015 May; 27(3):241-8. PubMed ID: 25775190
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential.
    Tsou PS; Varga J; O'Reilly S
    Nat Rev Rheumatol; 2021 Oct; 17(10):596-607. PubMed ID: 34480165
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeted therapies for systemic sclerosis.
    Denton CP; Ong VH
    Nat Rev Rheumatol; 2013 Aug; 9(8):451-64. PubMed ID: 23567456
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Transforming growth factor beta as a therapeutic target in systemic sclerosis.
    Varga J; Pasche B
    Nat Rev Rheumatol; 2009 Apr; 5(4):200-6. PubMed ID: 19337284
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Systemic sclerosis: a prototypic multisystem fibrotic disorder.
    Varga J; Abraham D
    J Clin Invest; 2007 Mar; 117(3):557-67. PubMed ID: 17332883
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic Sclerosis.
    Li Y; Huang J; Guo M; Zuo X
    Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):234-41. PubMed ID: 26365208
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacotherapy of systemic sclerosis.
    Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
    Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
    Antic M; Distler JH; Distler O
    Curr Opin Pharmacol; 2013 Jun; 13(3):455-62. PubMed ID: 23747024
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis.
    Wei J; Bhattacharyya S; Varga J
    Curr Opin Rheumatol; 2010 Nov; 22(6):671-6. PubMed ID: 20693905
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Emerging targets of disease-modifying therapy for systemic sclerosis.
    Volkmann ER; Varga J
    Nat Rev Rheumatol; 2019 Apr; 15(4):208-224. PubMed ID: 30796362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.